INTRODUCTION
The mineralocorticosteroid receptor (MR) is a regulatory transcriptional factor that mediates aldosterone action within target tissues (see ref. [1] for a review). However, a number of questions remain unanswered about the structure and function of this receptor, most notably the nature and physiological significance of its interaction with receptor-associated proteins (hsp9O, hsp70, p59, etc.) and the identity of specific target sequences and transcription factors involved in the modulation of receptor activity. Another important aspect of MR physiology is its subcellular localization and the influence of ligands on its nuclear/cytoplasmic distribution. Studies on MR have been hampered for many years by its very low abundance. This is the reason why the native MR protein has not yet been purified, thus preventing generation of specific antibodies by classic immunological procedures. One alternative approach is the anti-idiotypic strategy, which has facilitated the production of H1OE antibody [2] . This monoclonal antibody recognizes the ligand-binding site of MR and has been used to detect it in the rabbit kidney [3, 4] , heart and blood vessels [5] . The deduced primary sequence of the cDNA encoding the human MR (hMR) [6] prompted us to use the anti-peptide approach to raise specific antibodies that could be directed against regions of the receptor other than the ligandbinding domain. We were particularly interested in producing monoclonal antibodies able to recognize multiple forms of the hMR, i.e. native and denatured forms, a valuable property often missing from polyclonal anti-peptide antibodies [7] [8] [9] .
We report here on the production and characterization of the monoclonal antibody FD4 directed againt a preselected sequence of hMR, located at its N-terminal domain, the least-conserved region among members of the steroid-hormone receptor super- in the cytoplasmic compartment of cells. After aldosterone exposure, intense nuclear immunostaining appeared in a timedependent manner, consistent with stable nuclear localization of the receptor. Immunohistochemistry showed that antimineralocorticosteroids (ZK9 1587, SC9420, 18-vinylprogesterone) predominantly maintained a cytoplasmic distribution of hMR and inhibited its aldosterone-dependent nuclear localization. Thus, in our model, the nuclear/cytoplasmic partition of hMR is drastically different in the presence of antagonists from that in the presence of aldosterone. This phenomenon may contribute to their mechanism of action by preventing productive interaction of antagonist-receptor complex with specific DNA sequences in aldosterone target cells.
family. This anti-peptide antibody interacts with both native and denatured forms of the receptor as demonstrated by densitygradient analyses, immunoprecipitation assays, Western-blot and immunohistochemical experiments.
Although antimineralocorticosteroid compounds bind with high affinity to MR, their antagonistic effects seem to intervene at several molecular levels of the signal-transduction pathway. To investigate the effects of various agonist and antagonist ligands on the nuclear/cytoplasmic localization of hMR, immunohistochemical studies have been performed with the new monoclonal anti-peptide antibody. In the present paper, we provide evidence that the nature of the ligand markedly modifies the intracellular distribution of hMR, giving additional support for a specific function for MR in distinguishing between aldosterone and antimineralocorticosteroids.
MATERIALS AND METHODS Peptides
The primary sequence of hMR was analysed by computerized methods in a search for suitable peptides. Peptide sequences deduced from hMR cDNA [6] were selected for their high index of immunogenicity and potential for producing specific antibodies. These sequences are not found in the primary structure of other steroid receptors, in particular the glucocorticosteroid receptor (GR). A high score for hydrophilicity, a high probability of flexibility, protrusion and secondary structure of peptide sequences predicted a large immunogenic response [10] . One peptide designated RU54869 was synthesized by Roussel-Uclaf Laboratories and corresponds to the sequence hMR-(412-422). It was conjugated to keyhole limpet haemocyanin or to BSA using glutaraldehyde [11] . The ability of purified FD4 to interact with hMR was further determined by density-gradient analysis. After centrifugation, the pellets were washed and boiled in SDS buffer before electrophoresis.
The gel was then subjected to autoradiography. antagonist [15] , by measuring the amount of labelled receptor recovered in both the low-salt extract referred to as the cytosol fraction, and the high-salt extract, considered to be the nuclear fraction. Figure 5 shows that the [3H]aldosterone-hMR complexes were mostly detected in the nuclear fraction, whereas after incubation with ZK91 587, most of the hMR was recovered in the cytosol fraction, suggesting an impaired nuclear translocation of the receptor after antagonist binding. The effects of aldosterone on the intracellular localization of hMR were also examined by immunohistochemistry. When compared with the hormone-free condition (Figure 6a) , incubation with 50 nM aldosterone for 1 h induced clearly visible nuclear staining (Figure 6b) . After 24 h of incubation with the hormone (Figure 6c ), nuclear staining was accompanied by a concomitant decrease in cytoplasmic labelling, indicating an aldosterone-induced nuclear localization of the recombinant hMR. Time-course studies indicated that the percentage of cells showing exclusive nuclear staining increased during the first 4 h and remained stable for the following 24 h.
The subcellular immunolocalization of hMR was examined after exposure to spironolactone (SC9420), another aldosterone antagonist [16] , alone or in combination with aldosterone. The subcellular distribution of the immunolabelling was quantitatively analysed by classifying the positively staining cells into three categories: C, exclusively cytoplasmic labelling; C + N, nuclear and cytoplasmic immunostaining; N, predominantly nuclear labelling. Figure 7 details the results of this analysis and gives an example ofeach category of subcellular immunolabelling (C, C + N and N). In the absence of hormone, 85 % of the positive cells showed cytoplasmic labelling (C category). After 4 h treatment with 50 nM aldosterone, 50 % of the cells displayed exclusive nuclear labelling (N). In contrast, immunoreactive hMR was recovered mostly in the cytoplasmic compartment after treatment with 1 usM SC9420. Simultaneous treatment with aldosterone and SC9420 led also to predominantly cytoplasmic labelling, with only 10% of the cells showing nuclear staining (N). MR belongs to the superfamily of so-called 'nuclear receptors', although its intracellular localization and regulation by aldosterone agonists and antagonists remain poorly characterized. In the absence of hormone, indirect immunodetection with FD4 showed that the recombinant hMR is localized, almost exclusively, in the cytoplasmic compartment of infected insect cells, whereas some immunoreactive hMR could be detected in the nucleus. Our results confirmed the data obtained by both immunofluorescence techniques [9, 12] and confocal laser scanning microscopy [20] in the baculovirus overexpression system. Moreover, the aldosterone-induced nuclear translocation of the endogenous receptor has also been demonstrated in mouse macrophage cells by immunocytochemistry [20] .
In contrast with oestrogen and progesterone receptors located in the nucleus [21, 22] , the cytoplasmic distribution of unliganded MR resembles that reported for GR by most authors [13, [23] [24] [25] [26] . The presence of unliganded GR in the nucleus has recently been described [27] [28] [29] . However, it has been argued that the intracellular localization of GR is largely dependent on the experimental conditions (fixative procedures, presence of detergent, tumoral or overexpressing cellular models) [27] . Indeed, these apparently discrepant observations may reflect the nuclearcytoplasmic shuttling of GR [30] . The recycling mechanism by which the receptor passively diffuses into the cytoplasm and is actively translocated back to the nucleus may in fact be a general phenomenon in all experimental models for steroid receptors [30, 31] .
We have examined whether aldosterone or its antagonists modify the nucleocytoplasmic distribution of hMR. We showed that aldosterone-bound receptor was predominantly localized in the nucleus, suggesting that the hormone might de-repress the activity of putative nuclear localization signals. As far as GR is concerned, two hormone-dependent nuclear localization signals have been described, one (NL1) located in the hinge region of receptors next to the C-terminal site of the DNA-binding domain and the other (NL2) included in the ligand-binding domain [24, 26] . NL1, defined as a 28-amino acid fragment, contains the nuclear localization signal of the Simian Virus 40 large Tantigen [32] . Such signals remain to be identified for MR but, by sequence alignment with other steroid receptors, the segment 660-688 of hMR may correspond to the NLI motif.
In contrast with aldosterone, antimineralocorticosteroids SC9420, 18-vinylprogesterone and ZK91587 did not promote nuclear accumulation of hMR. These results are in agreement with previous biochemical studies which reported that, unlike aldosterone-receptor complexes, receptors labelled with spirolactones (SC26304 or prorenone) were not recovered in the nucleus after subcellular fractionation [33, 34] . These latter observations have been interpreted to reflect an absence of nuclear translocation of MR and/or by a low affinity of antagonistreceptor complexes for nuclear acceptors [35] . In the light of our data, we propose that antagonist-receptor complexes are translocated into the nucleus but aldosterone antagonists are unable to keep the receptor in the nuclear compartment. The alteration of receptor recycling kinetics is likely, as we were able to observe a weak but significant nuclear staining after treatment with antagonists, a result consistent with the detection of some specific nuclear binding of spironolactone by autoradiography [36] .
Our results demonstrate that the intracellular distribution of hMR is differentially regulated by aldosterone and antimineralocorticosteroids. Distinct changes in the receptor con-formation and/or in its phosphorylation state, for instance, induced by these ligands could be responsible for the modification of the nuclear/cytoplasmic distribution of the receptor. Antimineralocorticosteroids have been shown to destabilize the hetero-oligomeric structure of MR, dissociating very rapidly from the receptor and facilitating the release of the associated protein, hsp9O [37, 38] . We propose that the mechanism of action of antimineralocorticosteroids involves rapid dissociation kinetics, making stable ligand-receptor complexes unsustainable, and the absence of nuclear retention, both properties co-operating to prevent productive interaction of the receptor with specific DNA sequences in mammalian aldosterone target cells.
